Navigation Links
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
Date:9/25/2007

PINE BROOK, N.J., Sept. 25 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced it has been awarded a contract for $12 million for advanced development of Anthim(TM), the company's late-stage anthrax therapeutic. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, under Contract No. HHSN272200700035C. To date, Elusys has received more than $32 million from NIAID/BARDA and the Department of Defense in support of Anthim and the company's Heteropolymer Antibody(TM) technology.

Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented on the award, "Elusys is encouraged by the continued support from the U.S. Government and we look forward to extending our collaboration with NIAID/BARDA. We are confident that Elusys has developed a highly effective and valuable anthrax therapeutic for procurement under Project BioShield for addition to the U.S. Government's Strategic National Stockpile."

Dr. Posillico continued, "Inhalation of anthrax spores rapidly leads to death if patients are not treated immediately with specific antibiotics. Typically, victims of inhalation anthrax experience only vague symptoms until it is too late, when they are in toxemia, leaving antibiotics largely ineffective. Anthrax vaccines are also ineffective unless victims are immunized well in advance of exposure. Anthim represents a 'just in time anthrax therapeutic,' that in relevant models has demonstrated complete protection against an anthrax spore challenge with a single prophylactic dose, and has shown significant protection when administered up to two days after a lethal spore challenge,
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
9. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... conference call to report its second quarter 2014 financial ... and outlook on Thursday, August 7, 2014 at 8:30 ... The call can be accessed by dialing ... prior to the start of the call and providing ...
(Date:7/24/2014)... MINNEAPOLIS, July 24, 2014  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to ... the fiscal 2015 first quarter ended June 30, 2014.  ... ®  PC Neuromodulation System grew 19% to $4.1 ... first quarter of the prior year.  Total revenue ...
(Date:7/24/2014)... Calif. , July 24, 2014 Amgen (NASDAQ: ... its second quarter financial results on Tuesday, July 29, 2014, ... will be followed by a conference call with the investment ... Amgen will be Robert A. Bradway , chairman and ... team. Live audio of the conference call will ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... 2011 LaVoie Group, the acknowledged leader in life ... received a Gold Award in the 24th Annual International ... Inc. LaVoie Group also received Honors for the agency,s ... of 60% fueled by expansion of client business in ...
... NEW YORK, March 14, 2011 Reportlinker.com announces ... in its catalogue: Medical ... http://www.reportlinker.com/p0453765/Medical-Devices-Market-in-Europe-2008-2012.html Medical devices ... examination, surgery or treatment of patients. These devices ...
Cached Medicine Technology:LaVoie Group Wins Gold Mercury Award For Medical Device Company, Alphatec Spine 2Reportlinker Adds Medical Devices Market in Europe 2008-2012 2
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... 26, 2014 “Today, we introduce our ... clients all over the world. All these models are ... designed for the UK market,” says the CEO of ... suppliers of women’s special occasion outfits. , Ladies have ... comes. DressesOnlineShops.co.uk is one of the best choices for ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides ... report provides value, in millions of US dollars, volume ... market segments – Rigid Non-Video Sinuscopes. , The report ... each of these market categories, and global corporate-level profiles ... and deals related to the Sinuscopes market wherever available. ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York, New York (PRWEB) July 26, 2014 ... continue to be filed in U.S. courts, Bernstein ... calling on federal health regulators to ban uterine morcellation. ... individuals include a 46-year-old mother of four from California ... of uterine cancer called leiomyosarcoma just 10 days after ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... Inc. (Nasdaq: ISTA ), today announced it has ... that the Dermatologic and Ophthalmic Drugs Advisory Committee will review ... on June 26, 2009. , , On November 13, ... FDA for Bepreve as an eye drop treatment for ocular ...
... increase collaboration and resource-sharing in global PD scientific community ... The Michael J. Fox Foundation for Parkinson,s Research announced ... a resource-rich virtual workplace that MJFF hopes will become ... collaborating and conversing across the globe. MJFF,s goal in ...
... by any other name is still a rose, but ... ,athlete, and ,jock, are sometimes used interchangeably, but they ... University at Buffalo researcher Kathleen E. Miller, Ph.D. "In ... gender norms, these two identities represent very different perspectives ...
... Aon Affinity , a subsidiary of Aon Corporation ... Organization has launched the NSO Marketplace(SM) to offer ... insurance, risk management, professional and personal needs of the nursing community. For ... professional liability insurance to over 675,000 nurses in the ...
... method could boost survival, German study shows , ... approach to performing radical hysterectomy in early-stage cervical ... and local tumor recurrence, a German study shows. ... is a modified version of traditional radical hysterectomy. ...
... , Complimentary Continuing Education Lectures for Healthcare Professionals , ... is a challenging diagnosis which carries a poor prognosis ... several critical signaling and tumor suppressor pathways. While current ... improving outcomes for patients. In order to do this, ...
Cached Medicine News:Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 2Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 3Health News:Don't mistake an athlete for a 'toxic jock' 2Health News:Exclusive Marketplace for Nursing Professionals Launched by Nurses Service Organization 2Health News:Exclusive Marketplace for Nursing Professionals Launched by Nurses Service Organization 3Health News:Adult Glioblastoma: Best Approaches to a Challenging Diagnosis 2
These claw forceps are single-action with sturdy teeth that provide a broad grasping area to hold the gallbladder securely during removal....
This is a single-action instrument that features a spring handle....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: